Home › Funds › GREAT POINT PARTNERS LLC › DRUG
GREAT POINT PARTNERS LLC position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
GREAT POINT PARTNERS LLC reported holding 109,603 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$7.7M, representing 1.62% of its reported portfolio and ranking #23 among its reported holdings. GREAT POINT PARTNERS LLC has disclosed DRUG holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GREAT POINT PARTNERS LLC's DRUG position evolved
GREAT POINT PARTNERS LLC first disclosed a stake in DRUG in Q1 2026 at 220,000 shares (US$16.1M). Across 2 filings, GREAT POINT PARTNERS LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 109,603 shares valued at US$7.7M — a reduction of -110,397 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 220.00K | $16.05M | New |
| Q2 2026 | 109.60K | $7.69M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 77 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$63.2M), Vivo Capital, LLC (US$39.1M), Vestal Point Capital, LP (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Cormorant Asset Management, LP 900.00K sh · $63.18M · Q2 2026
- Vivo Capital, LLC 557.17K sh · $39.11M · Q2 2026
- Vestal Point Capital, LP 545.00K sh · $38.26M · Q2 2026
- BRAIDWELL LP 483.82K sh · $33.96M · Q2 2026
- Parkman Healthcare Partners LLC 205.05K sh · $14.39M · Q2 2026
- MPM BioImpact LLC 202.11K sh · $14.19M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 92.75K sh · $6.51M · Q2 2026
- Ikarian Capital, LLC 88.95K sh · $6.24M · Q2 2026
- Sio Capital Management, LLC 73.95K sh · $5.19M · Q2 2026
- B Group, Inc. 67.50K sh · $4.74M · Q2 2026
- Artia Global Partners LP 38.41K sh · $2.70M · Q2 2026
- KVP Capital Advisors, LP 31.81K sh · $2.23M · Q2 2026
More on GREAT POINT PARTNERS LLC
FAQ
How long has GREAT POINT PARTNERS LLC held DRUG?
GREAT POINT PARTNERS LLC has disclosed DRUG holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is GREAT POINT PARTNERS LLC's current position in DRUG?
As of Q2 2026, GREAT POINT PARTNERS LLC holds 109.60K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $7.69M, representing 1.62% of its reported portfolio and ranking #23.
Has GREAT POINT PARTNERS LLC been buying or selling DRUG?
In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC reduced its position in DRUG.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vivo Capital, LLC, Vestal Point Capital, LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.